HKEX:2315 - Biocytogen Pharmaceuticals (Beijing) Co Ltd Biocytogen Pharmaceuticals (Be
Sector: Health Care, Industry: Biotechnology
Add to Watchlist
   
Add Alert 


Yahoo Finance

HKD 25.2    -0.25 (-0.98%)
Show Basic Chart | 3M    6M    1Y    3Y    5Y          

23 Sep 2022


Loading...
Loading...
Loading...

General

CEO: Dr. Yuelei Shen Ph.D.

Headquarters: HK

Employees: 0

Homepage

Description

Biocytogen Pharmaceuticals (Beijing) Co Ltd is a biopharmaceutical and pre-clinical research services company. It has two Core Products, YH003 and YH001. YH003 is a recombinant humanized agonistic anti-Cluster of Differentiation 40 (CD40) Immunoglobulin G2 (IgG2) monoclonal antibody and YH001 is a recombinant humanized anti-CTLA-4, a protein receptor expressed constitutively on T cells that functions as an immune checkpoint and downregulates immune responses, Immunoglobulin G1 (IgG1) monoclonal antibody. YH003 is being developed for pancreatic ductal adenocarcinoma, melanoma and other advanced solid tumors. YH001 is being developed for hepatocellular carcinoma (HCC), non-small-cell lung carcinoma (NSCLC) and other solid tumors.

Your Holdings
Dashboard
Portfolio
Options
Other Assets

Tools
Screener
Risk Manager
Other Assets
Watchlist
Alerts
Notes
Wall
Community
Forum
Blogs
Instagram
Facebook
Shared Portfolios
Shared Screeners

Collab with Brokerages
Moomoo x StocksCafe
Webull x StocksCafe
Tiger x StocksCafe

Help
Quickstart Guides
StocksCafe Academy
StocksCafe Youtube Channel

About StocksCafe
Our Story
Send Feedback
Pricing
Market
Singapore
Hong Kong
Tokyo
Kuala Lumpur
United States
London
Shenzhen
Shanghai
Bombay
National (India)
Indexes
Singapore Savings Bonds
Singapore T-Bills
CoinGecko
Your Account
Settings
Subscriptions
Referrals
Messages
Profile
IG    FB    YouTube

About · FAQs · StocksCafe © 2022 · Privacy · Terms